WO2023237689A1 - Combinations comprising vitamin c and lactobacillus rhamnosus - Google Patents
Combinations comprising vitamin c and lactobacillus rhamnosus Download PDFInfo
- Publication number
- WO2023237689A1 WO2023237689A1 PCT/EP2023/065400 EP2023065400W WO2023237689A1 WO 2023237689 A1 WO2023237689 A1 WO 2023237689A1 EP 2023065400 W EP2023065400 W EP 2023065400W WO 2023237689 A1 WO2023237689 A1 WO 2023237689A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- combination
- vitamin
- lactobacillus rhamnosus
- disease
- blautia
- Prior art date
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 135
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 65
- 229960005070 ascorbic acid Drugs 0.000 title description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 63
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 63
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 63
- 239000011718 vitamin C Substances 0.000 claims abstract description 63
- 210000002429 large intestine Anatomy 0.000 claims abstract description 40
- 241001112693 Lachnospiraceae Species 0.000 claims abstract description 31
- 241001202853 Blautia Species 0.000 claims abstract description 29
- 241000192125 Firmicutes Species 0.000 claims abstract description 26
- 241001465754 Metazoa Species 0.000 claims abstract description 22
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 claims description 23
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 20
- 208000024714 major depressive disease Diseases 0.000 claims description 18
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 18
- 230000003111 delayed effect Effects 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 14
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 14
- 241000123777 Blautia obeum Species 0.000 claims description 13
- 241001038648 Blautia wexlerae Species 0.000 claims description 13
- 208000011231 Crohn disease Diseases 0.000 claims description 13
- 206010022489 Insulin Resistance Diseases 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 10
- 235000020824 obesity Nutrition 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 9
- 208000023328 Basedow disease Diseases 0.000 claims description 9
- 208000037384 Clostridium Infections Diseases 0.000 claims description 9
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims description 9
- 206010054236 Clostridium difficile infection Diseases 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 9
- 206010016654 Fibrosis Diseases 0.000 claims description 9
- 208000015023 Graves' disease Diseases 0.000 claims description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 9
- 206010033645 Pancreatitis Diseases 0.000 claims description 9
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 9
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 9
- 238000009825 accumulation Methods 0.000 claims description 9
- 201000003229 acute pancreatitis Diseases 0.000 claims description 9
- 201000008937 atopic dermatitis Diseases 0.000 claims description 9
- 208000029560 autism spectrum disease Diseases 0.000 claims description 9
- 230000007882 cirrhosis Effects 0.000 claims description 9
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 9
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 201000011461 pre-eclampsia Diseases 0.000 claims description 9
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- 239000006186 oral dosage form Substances 0.000 claims description 8
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 24
- 230000009286 beneficial effect Effects 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 6
- 229930003231 vitamin Natural products 0.000 description 45
- 235000013343 vitamin Nutrition 0.000 description 45
- 239000011782 vitamin Substances 0.000 description 45
- 229940088594 vitamin Drugs 0.000 description 45
- 239000006041 probiotic Substances 0.000 description 44
- 235000018291 probiotics Nutrition 0.000 description 44
- 230000000529 probiotic effect Effects 0.000 description 43
- 150000003722 vitamin derivatives Chemical class 0.000 description 42
- 239000011248 coating agent Substances 0.000 description 16
- 238000000576 coating method Methods 0.000 description 16
- 210000001072 colon Anatomy 0.000 description 16
- 239000000463 material Substances 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 244000005709 gut microbiome Species 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 210000000813 small intestine Anatomy 0.000 description 9
- 241000186660 Lactobacillus Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229940039696 lactobacillus Drugs 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000002702 enteric coating Substances 0.000 description 4
- 238000009505 enteric coating Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 235000021391 short chain fatty acids Nutrition 0.000 description 4
- 150000004666 short chain fatty acids Chemical class 0.000 description 4
- 210000003384 transverse colon Anatomy 0.000 description 4
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 241000246724 Blautia obeum A2-162 Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 229920003142 Eudragit® S 12,5 Polymers 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 241000254697 Lactobacillus rhamnosus HN001 Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- -1 curdulan Chemical compound 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940098462 oral drops Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Definitions
- the present invention relates to combinations comprising vitamin C and Lactobacillus rhamnosus and uses thereof in improving gut health in animals and humans. It was found that a combination of vitamin C and Lactobacillus rhamnosus, when delivered to the large intestine, increases the abundance of beneficial bacteria in the intestinal tract.
- Firmicutes is a phylum of bacteria comprising beneficial bacteria commonly found in the gut microbiome of humans and animals. Some members of the Firmicutes phylum are probiotic (such as Lactobacillus), and/or are known for producing butyrate. Butyrate has many health benefits: butyrate is a source of energy for the cells of the gut lining, stimulates the production of glutathione, is a natural antioxidant, controls intestinal inflammation and supports a strong gut lining, helps prevent cancer by preventing cancer cells from developing, and encourages the production of hormones for a healthy metabolism (Rinninella et al., What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases (2019); Hamer HM et al., The role of butyrate on colonic function (2008)).
- the Lachnospiraceae family of bacteria belongs to the phylum Firmicutes and is a predominant group of bacteria in the gut microbiota of healthy subjects (Vacca, M et al., The Controversial Role of Human Gut Lachnospiraceae (2020); Lozupone, CA et al., Diversity, stability and resilience of the human gut microbiota (2012)).
- Lachnospiraceae form one of the main producers of shortchain fatty acids (SCFAs). SCFAs are bacterial metabolites known to possess several antiinflammatory and antioxidant effects (Koh, A et al., From Dietary Fiber to Host Physiology: Short- Chain Fatty Acids as Key Bacterial Metabolites (2016)).
- Lachnospiraceae have been found to be decreased in people with Crohn’s disease and ulcerative colitis (Vacca, M etal., The Controversial Role of Human Gut Lachnospiraceae (2020); Sasaki, K et al, Construction of a model culture system of human colonic microbiota to detect decreased Lachnospiraceae abundance and butyrogenesis in the feces of ulcerative colitis patients (2019)).
- Blautia is a genus of anaerobic bacteria with probiotic characteristics that occur widely in the feces and intestines of mammals. Blautia populations are also seen to be decreased in people suffering from: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity, insulin resistance, Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation.
- Alzheimer’s disease ankylosing spondylitis
- autism spectrum disorder atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease
- Graves’ disease HIV, IBD with
- Blautia wexlerae has been found to be decreased in obese people, those with insulin resistance, and especially in people exhibiting both conditions. Conversely, lean adults have high populations of this microorganism in their microflora. Further, Blautia wexlerae exerts an anti-inflammatory effect on various blood cells, and thus a higher population can decrease chronic inflammation which is commonly observed in many chronic conditions. Another Blautia species, Blautia obeum can inhibit the proliferation of C.
- W02020/043797 discloses that vitamins can be useful to increase the growth of certain beneficial bacteria in the intestine. However, W02020/043797 does not describe that vitamins can be used in combination with probiotics to increase the abundance of other beneficial bacteria.
- the human gut is home to hundreds of different microbes, and it would be desirable to be able to boost specific beneficial bacteria. In particular, it would be desirable to increase the abundance of Firmicutes, Lachnospiraceae, and/or Blautia bacteria in the intestine to enhance wellness, improve health, and support the immune system.
- the present invention relates to the following items:
- Combination comprising vitamin C and Lactobacillus rhamnosus for the use according to any one of item 12-14, wherein the animal, including a human, is experiencing at least one condition selected from: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity, insulin resistance, Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation.
- Alzheimer’s disease ankylosing spondylitis
- autism spectrum disorder atopic dermatitis
- cirrhosis colorectal cancer
- Crohn’s disease Graves’ disease
- HIV IBD with Clostridium difficile infection
- Lactobacillus rhamnosus for the use according to any one of item 12-15, wherein the Lactobacillus rhamnosus is a Lactobacillus rhamnosus GG, preferably Lactobacillus rhamnosus DSM 32550.
- Firmicutes, Lachnospiraceae, and Blautia are bacteria known fortheir beneficial effects on human health.
- the present inventors have found that vitamin C in combination with Lactobacillus rhamnosus can boost the growth of Firmicutes, Lachnospiraceae, and Blautia bacteria in the large intestine, leading to an increase of Firmicutes, Lachnospiraceae, and Blautia levels in the gut.
- the present invention relates to combinations comprising vitamin C and Lactobacillus (Lacticaseibacillus) rhamnosus.
- the Lactobacillus (Lacticaseibacillus) rhamnosus is a Lactobacillus rhamnosus GG strain; more preferably Lactobacillus rhamnosus DSM 32550.
- the combination is for simultaneous and/or sequential administration.
- Vitamin C also known as L-ascorbic acid, is a water-soluble vitamin that is required for the biosynthesis of collagen, L-carnitine, and certain neurotransmitters. Vitamin C is also involved in protein metabolism. Further, vitamin C is an important physiological antioxidant. Vitamin C plays an important role in immune function and improves nutrient absorption. Vitamin C can be purchased from DSM GmbH. Alternative suppliers are, for example, TER Chemicals Distribution Group, BIOCHEM Bernburg GmbH, DVA International GmbH, Falken Trade GmbH, and Neupert Ingredients GmbH.
- Lactobacillus rhamnosus GG The most common Lactobacillus (Lacticaseibacillus) rhamnosus strain is Lactobacillus rhamnosus GG. It can be purchased, for example, from Chr. Hansen, Denmark, as LGG®. Lactobacillus (Lacticaseibacillus) rhamnosus DSM 32550 (Biocare Copenhagen, Denmark) has a genomic sequence which is 99.99% identical to the genomic sequence of LGG®. It can thus be considered that L. rhamnosus DSM 32550 is identical or equivalent to LGG® for practical purposes. Therefore, L. rhamnosus DSM 32550 will herein be referred to as a “Lactobacillus rhamnosus GG”.
- Lactobacillus rhamnosus strains are, inter alia, Lactobacillus rhamnosus HN001 (Howaru; Danisco/DuPont), Lactobacillus rhamnosus GR-1® (Chr. Hansen, Denmark), and Lactobacillus rhamnosus Rosell-11 (Lallemand, Canada).
- Lactobacillus (Lacticaseibacillus) rhamnosus DSM 32550 (Biocare Copenhagen) is a preferred strain according to the present invention. It has been deposited at Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Inhoffenstr. 7B, D-38124 Braunschweig, Germany, according to the Budapest Treaty on 6. July 2017. The accession number given by the International Depository Authority is DSM 32550.
- the combination of the present invention is for simultaneous administration.
- the combination for simultaneous administration is a fixed combination.
- a free combination can also be used.
- the combination is for sequential administration.
- the combination for sequential administration is a free combination.
- the combination is an oral dosage form; more preferably, it is a solid oral dosage form.
- the combinations of the invention are for use in the treatment of a patient that is in need of increasing the abundance of Firmicutes, Lachnospiraceae, and/or Blautia in the large intestine.
- said patient is suffering from Crohn’s disease or ulcerative colitis.
- the (pharmaceutical) combinations of the invention are for use in the treatment of a patient that is in need of increasing the abundance of Blautia, preferably Blautia obeum and/or Blautia wexlerae, in the large intestine.
- said patient is suffering from one or more of the following: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity, insulin resistance, Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation.
- Alzheimer’s disease ankylosing spondylitis
- autism spectrum disorder atopic dermatitis
- cirrhosis colorectal cancer
- Crohn’s disease Graves’ disease
- HIV IBD with Clostridium difficile infection, lung cancer
- MDD major depressive disorder
- NMOSD neuromyelitis optica spectrum disorders
- obesity insulin resistance
- Parkinson’s disease
- the present invention relates to vitamin C and Lactobacillus rhamnosus (i.e. , a combination of vitamin C and Lactobacillus rhamnosus) for use in improving gut health in an animal.
- Said improvement comprises or consists of increasing the abundance of Firmicutes, Lachnospiraceae and/or Blautia in the large intestine of said animal.
- the vitamin C and Lactobacillus rhamnosus is for use in increasing the abundance of Firmicutes, Lachnospiraceae and/or Blautia in the large intestine (colon) of an animal, wherein said use preferably comprises delivering the vitamin C and Lactobacillus rhamnosus to the large intestine.
- the animal is a human.
- Blautia obeum or Blautia wexlerae are the preferred Blautia bacteria to be increased.
- the vitamin C and Lactobacillus rhamnosus is preferably directly delivered to the large intestine. That is, the vitamin is delivered/ administered in a manner such that the vitamin is not absorbed in the stomach and/or small intestine; rather the vitamin and the probiotic is delivered/ administered to the distal intestinal tract, preferably the large intestine (colon). This is preferably done by delivering/ administering the vitamin C and Lactobacillus rhamnosus in a delayed-release formulation. Oral administration is preferred.
- the animal is experiencing one or more condition(s) selected from the group consisting of: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity, insulin resistance, Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation.
- condition(s) selected from the group consisting of: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy
- the Lactobacillus rhamnosus used is a Lactobacillus rhamnosus GG.
- Lactobacillus rhamnosus DSM 32550 is particularly preferred.
- the present invention relates to a method of increasing the abundance of Firmicutes, Lachnospiraceae and/or Blautia in the intestine, preferably the large intestine, comprising administering to the animal an effective dose of vitamin C and Lactobacillus rhamnosus (preferably, Lactobacillus rhamnosus GG, in particular Lactobacillus rhamnosus DSM 32550).
- the method is for improving intestinal health in an animal, including a human, wherein said improvement comprises increasing the abundance of Firmicutes, Lachnospiraceae and/or Blautia in the large intestine.
- the animal is a human.
- the vitamin C and the Lactobacillus rhamnosus is delivered directly to the large intestine. Delivery to the large intestine can be achieved by administering the vitamin C and the Lactobacillus rhamnosus as a delayed- release formulation.
- the Blautia bacteria to be increased are of the species Blautia obeum and/or Blautia wexlerae.
- the methods of the invention can be used to treat, prevent, and/or lessen the symptoms in an animal, including a human, in need thereof, of one or more of the following: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity, insulin resistance, Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation.
- Alzheimer’s disease ankylosing spondylitis
- autism spectrum disorder atopic dermatitis
- cirrhosis colorectal cancer
- Crohn’s disease Graves’ disease
- HIV IBD with Clostridium difficile infection, lung cancer
- the animal including a human, is experiencing one or more condition(s) selected from the group consisting of: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity, insulin resistance, Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation.
- condition(s) selected from the group consisting of: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD
- the Lactobacillus rhamnosus used is Lactobacillus rhamnosus GG.
- the Blautia bacteria to be increased are of the species Blautia obeum and/or Blautia wexlerae.
- the vitamin C (ascorbic acid) dose is up to 2000 mg/day, preferably 100-2000 mg/day; more preferably 200-1000 mg/day.
- vitamin C is dosed/ administered in an amount such that its local concentration in the colon is at least 0.05 g/L, preferably at least 0.1 g/L, most preferably at least 0.33 g/L.
- Preferred local concentrations in the colon range from about 0.05 g/L to about 1 .5 g/L, more preferably from about 0.1 g/L to about 1 g/L, most preferably from about 0.2 g/L to about 0.5 g/L.
- the dosage of the Lactobacillus rhamnosus can be up to 5E+10 cfu/day.
- the dosage range is from 1 E+08 to 1 E+10 cfu/day, more preferably from 1 E+09 to 5E+10 cfu/day.
- the Lactobacillus rhamnosus is a Lactobacillus rhamnosus GG. Lactobacillus rhamnosus DSM 32550 is particularly preferred.
- a “fixed combination” is a combination that delivers both actives (i.e., the vitamin and the probiotic) at the same time to a patient.
- a solid oral dosage form e.g., a tablet or capsule
- a liquid oral dosage form e.g., oral drops
- a fixed combination is another example of a fixed combination.
- a “free combination” is a combination that allows to administer/consume both actives (i.e., the vitamin and the probiotic) separately, i.e. one at a time. Treatment regimens in which the vitamin and the probiotic are not administered/consumed by the same route and/or are not administered/consumed at the same time require free combinations.
- Simultaneous administration/consumption can be done both by using a fixed combination and a free combination.
- Sequential administration/consumption requires a free combination; fixed combinations are not suitable for sequential administration/consumption.
- free combinations are more versatile: they are suitable for sequential administration/consumption and - if both actives are administered/consumed on the same day - also for simultaneous administration/consumption.
- Fixed combinations are only suitable for simultaneous administration/consumption if both ingredients (i.e., the vitamin and the probiotic) are to be administered/consumed at the same time of the same day; if, however, the vitamin and the probiotic are to be administered/consumed on the same day but separately, fixed combinations are not suitable.
- administering means to give or to deliver an active to a human or animal; likewise, the human or animal can take (consume) the active.
- delayed release refers to the release of the vitamin and/or the probiotic at a time later than immediately after administration.
- “delayed release” means delivery of the vitamin (and/or probiotic), upon oral administration, to the large intestine (colon) in a delayed manner relative to an immediate release formulation.
- Co-administering or “co-administration” means that the vitamin and/or the probiotic is delivered/ administered/ consumed simultaneously (i.e. , together), or separately but within a time frame of 24 hours.
- the vitamin can be delivered/ administered/ consumed first.
- the probiotic can be delivered/ administered/ consumed first.
- L. rhamnosus was recently renamed “Lacticaseibacillus rhamnosus”’, both names are used interchangeably herein, and both can be abbreviated as “L. rhamnosus”.
- the dosage of the probiotic can be up to 5E+10 cfu/day.
- the dosage range of the probiotic is from 1 E+08 to 1 E+10 cfu/day, more preferably from 1 E+09 to 5E+10 cfu/day.
- Delayed-release formulations are known in the art.
- the delayed-release formulations have an enteric coating (also referred to as enteric layer).
- the release of the vitamin and/or probiotic may be delayed until the small intestine. In another embodiment, the release is delayed until the distal small intestine. In yet another, preferred embodiment, the release of the vitamin and/or probiotic is delayed until the colon (large intestine).
- the vitamin and/or probiotic is formulated in a solid dosage form for oral administration.
- the formulation may be in the form of a capsule, pellet, bead, sphere, mini spheres, tablet, mini tablet, or granule, optionally coated with a delayed release coating that prevents the release of the active agent before the small intestine, preferably before the colon.
- Coating, or matrix materials for the delayed release of the vitamin and/or probiotic, in particular for targeted release in the ileum or the large intestine upon oral administration are known in the art. They can be subdivided into coating materials that disintegrate above a specific pH, coating materials that disintegrate after a specific residence time in the gastrointestinal tract and coating materials that disintegrate due enzymatic triggers specific to the microflora of a specific region of the intestines. Coating materials from different categories are commonly used in combinations. Coating materials of the different categories for targeting to the large intestine have been reviewed for example in Bansal et al. (Polim. Med. 2014, 44, 2,109-118).
- the delayed-release coating comprises at least one component selected from coating materials that disintegrate pH-dependently, coating materials that disintegrate time-dependently, coating materials that disintegrate due to enzymatic triggers in the intestinal environment (e.g., in the intestinal environment of the ileum and the large intestine), and combinations thereof.
- Coating materials that disintegrate pH-dependently include polyvinyl acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate HP-50, HP-55 or HP-55S, cellulose acetate phthalate, shellac, hydroxypropyl methylcellulose acetate succinate (HPMCAS), poly(methacrylic acid, ethyl acrylate) 1 :1 (Eudragit® L100-55, Eudragit® L30D-55), poly(methacrylic acid, methyl methacrylate) 1 :1 (Eudragit® L-100, Eudragit® L12.5), poly(methacrylic acid, methyl methacrylate) 1 :2 (Eudragit® S-100, Eudragit® S12,5, and Eudragit® FS30D).
- HPMCAS hydroxypropyl methylcellulose acetate succinate
- Coating materials that disintegrate time-dependently include Eudragit® RL, Eudragit®RS, and ethylcellulose.
- Coating materials that disintegrate due to enzymatic triggers in the large intestinal environment include chondroitin sulfate, pectin, guar gum, chitosan, inulin, lactulose, raffinose, stachyose, alginate, dextran, xanthan gum, locust bean gum, arabinogalactan, cyclodextrin, pullulan, carrageenan, scleroglucan, chitin, curdulan, levan, amylopectin, starch, amylose, resistant starch, and azo compounds being degraded by azo bonds splitting bacteria.
- the aim of this study was to investigate the effect of a combination of vitamin C and Lactobacillus rhamnosus on the composition of the gut microbiota in a long-term continuous fermentation experiment.
- Stabilization period After inoculation of the colon reactors with an appropriate fecal sample, a two-week stabilization period allowed the microbial community to differentiate in the different reactors depending on the local environmental conditions. During this period the basic nutritional matrix was provided to the SHIME to support the maximum diversity of the gut microbiota originally present in the faecal inoculum. 2. Control period: During this two-week reference period, the standard SHIME nutrient matrix was further dosed to the model for a period of 14 days. Analysis of samples in this period allowed to determine the baseline microbial community composition and activity in the different reactors, which is used as a reference for results obtained during the treatment.
- the probiotic strain used in this experiment was the Lactobacillus rhamnosus GG equivalent Lactobacillus rhamnosus DSM 32550 (Biocare Copenhagen).
- Lactobacillus rhamnosus DSM 32550 has a genomic sequence which is 99.99% identical to the genomic sequence of LGG®. It can therefore be considered that L. rhamnosus DSM 32550 is identical or equivalent to LGG® for practical purposes. In the Examples and Figures herein, Lactobacillus rhamnosus DSM 32550 will thus be referred to as a Lactobacillus rhamnosus GG strain.
- Samples for quantitative 16S-targeted Illumina sequencing were collected 3x/week during the last week of the control and treatment period.
- Next-generation 16S rRNA gene amplicon sequencing of the V3-V4 region was performed by LGC Genomics GmbH (Berlin, Germany) on samples from the medium-term SHIME experiment. Library preparation and sequencing were performed on an Illumina MiSeq platform with v3 chemistry.
- the 341 F (50-CCTACGGGNGGCWGCAG-30) and 785R (50- GACTACHVGGGTATCTAAKCC-30) primers were used as described by De Paepe et al. (2017) with the reverse primer being adapted to increase coverage.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
The present invention relates to a combination comprising vitamin C and Lactobacillus rhamnosus and its use for improving gut health in animals and humans. It was found that a combination of vitamin C and Lactobacillus rhamnosus, when delivered to the large intestine, increases the abundance of beneficial Firmicutes, Lachnospiraceae, Blautia bacteria in the intestinal tract.
Description
COMBINATIONS COMPRISING VITAMIN C AND LACTOBACILLUS RHAMNOSUS
FIELD OF THE INVENTION
The present invention relates to combinations comprising vitamin C and Lactobacillus rhamnosus and uses thereof in improving gut health in animals and humans. It was found that a combination of vitamin C and Lactobacillus rhamnosus, when delivered to the large intestine, increases the abundance of beneficial bacteria in the intestinal tract.
BACKGROUND OF THE INVENTION
Increasing evidence indicates that imbalances in the human gut microbiota (also referred to as “dysbiosis”) may be associated with Western diseases, including obesity and type 2 diabetes, as well as cardiovascular, autoimmune, and intestinal inflammatory disease. Thus, targeted modulation of the human gut microbiome intended to restore imbalances represents a potential therapeutic and preventive strategy and has attracted the attention of academics as well as those engaged in various industries. Public awareness and acceptance of substances that modulate the human gut microbiome continue to grow.
There is a consensus that certain live microorganisms have beneficial effects on human health. Firmicutes is a phylum of bacteria comprising beneficial bacteria commonly found in the gut microbiome of humans and animals. Some members of the Firmicutes phylum are probiotic (such as Lactobacillus), and/or are known for producing butyrate. Butyrate has many health benefits: butyrate is a source of energy for the cells of the gut lining, stimulates the production of glutathione, is a natural antioxidant, controls intestinal inflammation and supports a strong gut lining, helps prevent cancer by preventing cancer cells from developing, and encourages the production of hormones for a healthy metabolism (Rinninella et al., What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases (2019); Hamer HM et al., The role of butyrate on colonic function (2008)).
The Lachnospiraceae family of bacteria belongs to the phylum Firmicutes and is a predominant group of bacteria in the gut microbiota of healthy subjects (Vacca, M et al., The Controversial Role of Human Gut Lachnospiraceae (2020); Lozupone, CA et al., Diversity, stability and resilience of the human gut microbiota (2012)). Lachnospiraceae form one of the main producers of shortchain fatty acids (SCFAs). SCFAs are bacterial metabolites known to possess several antiinflammatory and antioxidant effects (Koh, A et al., From Dietary Fiber to Host Physiology: Short-
Chain Fatty Acids as Key Bacterial Metabolites (2016)). Lachnospiraceae have been found to be decreased in people with Crohn’s disease and ulcerative colitis (Vacca, M etal., The Controversial Role of Human Gut Lachnospiraceae (2020); Sasaki, K et al, Construction of a model culture system of human colonic microbiota to detect decreased Lachnospiraceae abundance and butyrogenesis in the feces of ulcerative colitis patients (2019)).
Blautia is a genus of anaerobic bacteria with probiotic characteristics that occur widely in the feces and intestines of mammals. Blautia populations are also seen to be decreased in people suffering from: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity, insulin resistance, Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation. Moreover, increased Blautia was associated with good cognition and decreased systemic inflammation. One Blautia species, Blautia wexlerae has been found to be decreased in obese people, those with insulin resistance, and especially in people exhibiting both conditions. Conversely, lean adults have high populations of this microorganism in their microflora. Further, Blautia wexlerae exerts an anti-inflammatory effect on various blood cells, and thus a higher population can decrease chronic inflammation which is commonly observed in many chronic conditions. Another Blautia species, Blautia obeum can inhibit the proliferation of C. perfringens and vancomycin-resistant enterococci, which makes it a potential probiotic exerting probiotic functions (Hatziioanou D et al., Discovery of a novel lantibiotic nisin O from Blautia obeum A2-162, isolated from the human gastrointestinal tract. (2017)). Moreover, the intestinal microbiota of cholera patients were significantly different from that of healthy individuals, in which Blautia obeum showed a significant negative correlation with the colonization of Vibrio cholerae. (Alavi S. et a. Interpersonal Gut Microbiome Variation Drives Susceptibility and Resistance to Cholera Infection (2020)).
Recently, it was demonstrated that vitamins may modulate the human gut microbiome. W02020/043797 discloses that vitamins can be useful to increase the growth of certain beneficial bacteria in the intestine. However, W02020/043797 does not describe that vitamins can be used in combination with probiotics to increase the abundance of other beneficial bacteria. Moreover, the human gut is home to hundreds of different microbes, and it would be desirable to be able to boost specific beneficial bacteria. In particular, it would be desirable to increase the abundance
of Firmicutes, Lachnospiraceae, and/or Blautia bacteria in the intestine to enhance wellness, improve health, and support the immune system.
SUMMARY OF THE INVENTION
The present invention relates to the following items:
1) Combination comprising vitamin C and Lactobacillus rhamnosus.
2) Combination according to item 1 , wherein said combination comprises vitamin C and a Lactobacillus (Lacticaseibacillus) rhamnosus GG, preferably Lactobacillus rhamnosus DSM 32550.
3) Combination according to item 1 or item 2, wherein said combination is for simultaneous administration or delivery or consumption, and preferably wherein said combination is a fixed combination.
4) Combination according to item 1 or item 2, wherein said combination is for sequential administration or delivery or consumption, and preferably wherein said combination is a free combination.
5) Combination according to any one of item 1-4, wherein said combination is an oral dosage form, and wherein said combination is more preferably a solid oral dosage form.
6) Combination according to any one of items 1 -5, wherein said combination is for administration or delivery to the large intestine.
7) Combination according to any one of item 1 -6 for use as a medicament, a dietary supplement, or a food supplement.
8) Combination according to any one of item 1-7 for use in the treatment of a patient that is in need of increasing the abundance of Firmicutes, preferably Lachnospiraceae, in the large intestine.
9) Combination for the use according to item 8, wherein said patient is in need of increasing the abundance of Lachnospiraceae and is suffering from ulcerative colitis or Crohn’s disease.
10) Combination according to any one of item 1-7 for use in the treatment of a patient that is in need of increasing the abundance of Blautia, preferably Blautia obeum or Blautia wexlerae, in the large intestine.
11) Combination for the use according to item 10, wherein said patient is suffering from one or more of the following: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity, insulin resistance,
Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation.
12) Combination comprising vitamin C and Lactobacillus (Lacticaseibacillus) rhamnosus for use in increasing the abundance of Firmicutes, Lachnospiraceae, and/or Blautia in the large intestine of an animal, preferably a human, wherein said use comprises delivering the vitamin C and the Lactobacillus rhamnosus to the large intestine.
13) Combination comprising vitamin C and Lactobacillus rhamnosus for the use according to item 12, wherein the vitamin C and the Lactobacillus rhamnosus are delivered to the large intestine by a delayed-release formulation.
14) Combination comprising vitamin C and Lactobacillus rhamnosus for the use according to item 12 or item 13, wherein said use comprises administering the vitamin C and the Lactobacillus rhamnosus simultaneously and/or sequentially to the animal, preferably a human.
15) Combination comprising vitamin C and Lactobacillus rhamnosus for the use according to any one of item 12-14, wherein the animal, including a human, is experiencing at least one condition selected from: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity, insulin resistance, Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation.
16) Combination comprising vitamin C and Lactobacillus rhamnosus for the use according to any one of item 12-15, wherein the Lactobacillus rhamnosus is a Lactobacillus rhamnosus GG, preferably Lactobacillus rhamnosus DSM 32550.
17) Combination comprising vitamin C and Lactobacillus rhamnosus for the use according to any one of item 12-16, wherein the Blautia is Blautia obeum and/or Blautia wexlerae.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGURE 1 Average levels (log cells/mL) of Firmicutes bacteria in the lumen of the transverse colon upon treatment with Lactobacillus rhamnosus GG in the presence or absence of vitamin C, at the end of the control period (n=3) and at the end of the treatment period (n=3). Statistically significant differences are indicated with '*’ (p<0.05).
FIGURE 2 Average levels (log cells/mL) of Lachnospiraceae bacteria in the lumen of the transverse colon upon treatment with Lactobacillus rhamnosus GG in the presence or absence
of vitamin C, at the end of the control period (n=3) and at the end of the treatment period (n=3).
Statistically significant differences are indicated with “*’ (p<0.05).
FIGURE 3 Average levels (log cells/mL) of Blautia obeum/wexlerae bacteria in the lumen of the transverse colon upon treatment with Lactobacillus rhamnosus GG in the presence or absence of vitamin C, at the end of the control period (n=3) and at the end of the treatment period (n=3). Statistically significant differences are indicated with “*’ (p<0.05).
DETAILED DESCRIPTION OF THE INVENTION
Firmicutes, Lachnospiraceae, and Blautia are bacteria known fortheir beneficial effects on human health. The present inventors have found that vitamin C in combination with Lactobacillus rhamnosus can boost the growth of Firmicutes, Lachnospiraceae, and Blautia bacteria in the large intestine, leading to an increase of Firmicutes, Lachnospiraceae, and Blautia levels in the gut.
Hence, in a first aspect, the present invention relates to combinations comprising vitamin C and Lactobacillus (Lacticaseibacillus) rhamnosus. Preferably, the Lactobacillus (Lacticaseibacillus) rhamnosus is a Lactobacillus rhamnosus GG strain; more preferably Lactobacillus rhamnosus DSM 32550. The combination is for simultaneous and/or sequential administration.
Patent claims relating to a “combination” are product claims. The product of the present invention comprises two active ingredients: a vitamin (vitamin C) and a probiotic (Lactobacillus rhamnosus). For simultaneous and/or sequential administration, see definitions and embodiments below.
Vitamin C, also known as L-ascorbic acid, is a water-soluble vitamin that is required for the biosynthesis of collagen, L-carnitine, and certain neurotransmitters. Vitamin C is also involved in protein metabolism. Further, vitamin C is an important physiological antioxidant. Vitamin C plays an important role in immune function and improves nutrient absorption. Vitamin C can be purchased from DSM GmbH. Alternative suppliers are, for example, TER Chemicals Distribution Group, BIOCHEM Bernburg GmbH, DVA International GmbH, Falken Trade GmbH, and Neupert Ingredients GmbH.
The most common Lactobacillus (Lacticaseibacillus) rhamnosus strain is Lactobacillus rhamnosus GG. It can be purchased, for example, from Chr. Hansen, Denmark, as LGG®. Lactobacillus (Lacticaseibacillus) rhamnosus DSM 32550 (Biocare Copenhagen, Denmark) has
a genomic sequence which is 99.99% identical to the genomic sequence of LGG®. It can thus be considered that L. rhamnosus DSM 32550 is identical or equivalent to LGG® for practical purposes. Therefore, L. rhamnosus DSM 32550 will herein be referred to as a “Lactobacillus rhamnosus GG”.
Alternative Lactobacillus rhamnosus strains are, inter alia, Lactobacillus rhamnosus HN001 (Howaru; Danisco/DuPont), Lactobacillus rhamnosus GR-1® (Chr. Hansen, Denmark), and Lactobacillus rhamnosus Rosell-11 (Lallemand, Canada).
Lactobacillus (Lacticaseibacillus) rhamnosus DSM 32550 (Biocare Copenhagen) is a preferred strain according to the present invention. It has been deposited at Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Inhoffenstr. 7B, D-38124 Braunschweig, Germany, according to the Budapest Treaty on 6. July 2017. The accession number given by the International Depository Authority is DSM 32550.
In one embodiment, the combination of the present invention is for simultaneous administration. Preferably, the combination for simultaneous administration is a fixed combination. However, for simultaneous administration, a free combination can also be used.
In another embodiment, the combination is for sequential administration. The combination for sequential administration is a free combination.
Preferably, the combination is an oral dosage form; more preferably, it is a solid oral dosage form.
The combination of the present invention can be, for example, a pharmaceutical combination or composition, a dietary supplement, or a food supplement.
In another aspect, the present invention relates to vitamin C and Lactobacillus rhamnosus (i.e. , a combination of vitamin C and Lactobacillus rhamnosus) for use as a medicament.
Preferably, the combinations of the invention (e.g. pharmaceutical combinations) are for use in the treatment of a patient that is in need of increasing the abundance of Firmicutes, Lachnospiraceae, and/or Blautia in the large intestine. In one embodiment, said patient is suffering from Crohn’s disease or ulcerative colitis.
In another preferred embodiment, the (pharmaceutical) combinations of the invention are for use in the treatment of a patient that is in need of increasing the abundance of Blautia, preferably Blautia obeum and/or Blautia wexlerae, in the large intestine. Preferably, said patient is suffering from one or more of the following: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity, insulin resistance, Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation.
In a further aspect, the present invention relates to vitamin C and Lactobacillus rhamnosus (i.e. , a combination of vitamin C and Lactobacillus rhamnosus) for use in improving gut health in an animal. Said improvement comprises or consists of increasing the abundance of Firmicutes, Lachnospiraceae and/or Blautia in the large intestine of said animal. Specifically, the vitamin C and Lactobacillus rhamnosus is for use in increasing the abundance of Firmicutes, Lachnospiraceae and/or Blautia in the large intestine (colon) of an animal, wherein said use preferably comprises delivering the vitamin C and Lactobacillus rhamnosus to the large intestine. Preferably, the animal is a human. Blautia obeum or Blautia wexlerae are the preferred Blautia bacteria to be increased.
To achieve an increase of the abundance of Firmicutes, Lachnospiraceae and/or Blautia in the large intestine, the vitamin C and Lactobacillus rhamnosus is preferably directly delivered to the large intestine. That is, the vitamin is delivered/ administered in a manner such that the vitamin is not absorbed in the stomach and/or small intestine; rather the vitamin and the probiotic is delivered/ administered to the distal intestinal tract, preferably the large intestine (colon). This is preferably done by delivering/ administering the vitamin C and Lactobacillus rhamnosus in a delayed-release formulation. Oral administration is preferred.
In a preferred embodiment, the animal (including a human) is experiencing one or more condition(s) selected from the group consisting of: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity,
insulin resistance, Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation.
Preferably, the Lactobacillus rhamnosus used is a Lactobacillus rhamnosus GG. Lactobacillus rhamnosus DSM 32550 is particularly preferred.
In another aspect, the present invention relates to a method of increasing the abundance of Firmicutes, Lachnospiraceae and/or Blautia in the intestine, preferably the large intestine, comprising administering to the animal an effective dose of vitamin C and Lactobacillus rhamnosus (preferably, Lactobacillus rhamnosus GG, in particular Lactobacillus rhamnosus DSM 32550). The method is for improving intestinal health in an animal, including a human, wherein said improvement comprises increasing the abundance of Firmicutes, Lachnospiraceae and/or Blautia in the large intestine. Preferably, the animal is a human. Preferably, the vitamin C and the Lactobacillus rhamnosus is delivered directly to the large intestine. Delivery to the large intestine can be achieved by administering the vitamin C and the Lactobacillus rhamnosus as a delayed- release formulation. Preferably, the Blautia bacteria to be increased are of the species Blautia obeum and/or Blautia wexlerae.
The methods of the invention can be used to treat, prevent, and/or lessen the symptoms in an animal, including a human, in need thereof, of one or more of the following: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity, insulin resistance, Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation.
In a further aspect, the present invention relates to the use of vitamin C and Lactobacillus rhamnosus for increasing the abundance of Firmicutes, Lachnospiraceae and/or Blautia in the large intestine of an animal, preferably a human, wherein said use comprises delivering the vitamin C and the Lactobacillus rhamnosus to the large intestine. Preferably, the use comprises delivering/ administering the vitamin C and Lactobacillus rhamnosus to the large intestine by a delayed-release formulation. Preferably, the animal, including a human, is experiencing one or more condition(s) selected from the group consisting of: Alzheimer’s disease, ankylosing
spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity, insulin resistance, Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation. Preferably, the Lactobacillus rhamnosus used is Lactobacillus rhamnosus GG. Preferably, the Blautia bacteria to be increased are of the species Blautia obeum and/or Blautia wexlerae.
In the combinations, uses, and methods of the invention, preferably, the vitamin C (ascorbic acid) dose is up to 2000 mg/day, preferably 100-2000 mg/day; more preferably 200-1000 mg/day. In one embodiment, vitamin C is dosed/ administered in an amount such that its local concentration in the colon is at least 0.05 g/L, preferably at least 0.1 g/L, most preferably at least 0.33 g/L. Preferred local concentrations in the colon range from about 0.05 g/L to about 1 .5 g/L, more preferably from about 0.1 g/L to about 1 g/L, most preferably from about 0.2 g/L to about 0.5 g/L.
The dosage of the Lactobacillus rhamnosus can be up to 5E+10 cfu/day. Preferably, the dosage range is from 1 E+08 to 1 E+10 cfu/day, more preferably from 1 E+09 to 5E+10 cfu/day. Preferably, the Lactobacillus rhamnosus is a Lactobacillus rhamnosus GG. Lactobacillus rhamnosus DSM 32550 is particularly preferred.
Definitions and embodiments
As used throughout, the following definitions apply:
Patent claims relating to a “combination” or “pharmaceutical combination” are product claims. The product of the present invention comprises two active ingredients: a vitamin (vitamin C) and a probiotic (Lactobacillus rhamnosus).
A “combination for simultaneous administration” or a “combination for simultaneous consumption” is a combination that is suitable for simultaneous administration or consumption, respectively. By "simultaneous administration" or "simultaneous consumption”, it is meant that the vitamin and the probiotic bacteria are administered/consumed on the same day (i.e., with 24 hours). Said two active ingredients can be administered/consumed at the same time (for fixed combinations) or one at a time (for free combinations). For example, the vitamin can be administered/consumed in
one pill or tablet, while the probiotic is administered/consumed in another pill or tablet, wherein both pills/tablets are administered/consumed within 24 hours. In another example, the vitamin and the probiotic are formulated in the same composition and are administered/consumed at exactly the same time.
A “combination for sequential administration or consumption” is a combination that is suitable for sequential administration or consumption, respectively. By "sequential administration" or "sequential consumption”, it is meant that during a period of two or more days of continuous treatment, only one of the vitamin and the probiotic is administered/consumed on any given day. By way of example, the vitamin can be administered/consumed on day one, and the probiotic is administered/consumed only the next day (i.e., after more than 24 hours), or even later. The active ingredients can be administered/consumed in any order.
A “fixed combination” is a combination that delivers both actives (i.e., the vitamin and the probiotic) at the same time to a patient. A solid oral dosage form (e.g., a tablet or capsule) comprising both, the vitamin and the probiotic, is an example of a fixed combination. A liquid oral dosage form (e.g., oral drops) comprising both, the vitamin and the probiotic, is another example of a fixed combination.
A “free combination” is a combination that allows to administer/consume both actives (i.e., the vitamin and the probiotic) separately, i.e. one at a time. Treatment regimens in which the vitamin and the probiotic are not administered/consumed by the same route and/or are not administered/consumed at the same time require free combinations.
Simultaneous administration/consumption can be done both by using a fixed combination and a free combination. Sequential administration/consumption requires a free combination; fixed combinations are not suitable for sequential administration/consumption. Hence, free combinations are more versatile: they are suitable for sequential administration/consumption and - if both actives are administered/consumed on the same day - also for simultaneous administration/consumption. Fixed combinations are only suitable for simultaneous administration/consumption if both ingredients (i.e., the vitamin and the probiotic) are to be administered/consumed at the same time of the same day; if, however, the vitamin and the probiotic are to be administered/consumed on the same day but separately, fixed combinations are not suitable.
By "separate administration/consumption", it is meant that the vitamin and the probiotic are administered one at a time. Thus, separate administration/consumption can refer to both sequential administration/consumption and - when referring to the administration/consumption of both actives on the same day but one at a time - also to simultaneous administration/consumption.
“Administering” or “administration” means to give or to deliver an active to a human or animal; likewise, the human or animal can take (consume) the active.
The term “vitamin C” which can be used interchangeably with "ascorbic acid" also includes pharmaceutically acceptable salts thereof (e.g., sodium ascorbate and calcium ascorbate) and pharmaceutically acceptable esters thereof (in particular ascorbyl palmitate) and other pharmaceutically acceptable forms.
To “increase the abundance” of Firmicutes, Lachnospiraceae, or Blautia means to increase the level (or the amount, or number, or the population size) of Firmicutes, Lachnospiraceae, or Blautia compared to the respective control (i.e., the level/ amount/ number/ population size of Firmicutes, Lachnospiraceae, or Blautia when the combination of vitamin C and Lactobacillus rhamnosus has not been added).
The term “intestine” (or “gut”) as used herein refers to the portion of the gastrointestinal tract consisting of the small intestine and the large intestine. The “large intestine” (intestinum crassum) is the lower part of the gastrointestinal tract and is also referred to herein as “colon”.
"Direct delivery" or "directly delivered" means that the vitamin is formulated in a manner such that the vitamin is not absorbed in the stomach and/or small intestine; rather the vitamin is made available in the distal intestinal tract, preferably the large intestine (colon), where it is available to the microbiome. The vitamin is not part of a person's usual daily nutritional requirements (generally obtained through diet and conventional vitamin supplementation), and is administered in excess thereof. For human use, the preferred method according to the present invention is through a form which delays release until the large intestinal tract (colon) is reached. Alternatively, a large enough dose can be administered, so that only a portion of the administered vitamin is absorbed in the proximal small intestine, and the remainder, which is an effective dose, is available to the large intestinal tract; although not preferred, the latter method of delivery can be
used for humans as well. With respect to the probiotic, "direct delivery" or "directly delivered" means that the probiotic is formulated in a manner such that it is not released in the stomach and/or small intestine but rather it is made available in the distal intestinal tract, preferably the large intestine (colon).
A used herein, “delayed release” refers to the release of the vitamin and/or the probiotic at a time later than immediately after administration. Preferably, “delayed release” means delivery of the vitamin (and/or probiotic), upon oral administration, to the large intestine (colon) in a delayed manner relative to an immediate release formulation.
An “enteric layer” or “enteric coating” is a layer surrounding a core, wherein the core comprises the active agent and the layer confers resistance to gastric juice.
"Prevent" can include lessening the risk of an adverse condition occurring, lessening the symptoms of an adverse condition, lessening the severity of an adverse condition, and prolonging the time for occurrence of an adverse condition.
“Oral formulation” means that the vitamin and/or probiotic is formulated for oral administration/ consumption.
“Co-administering” or “co-administration” means that the vitamin and/or the probiotic is delivered/ administered/ consumed simultaneously (i.e. , together), or separately but within a time frame of 24 hours. The vitamin can be delivered/ administered/ consumed first. Likewise, the probiotic can be delivered/ administered/ consumed first.
“Lactobacillus rhamnosus” was recently renamed “Lacticaseibacillus rhamnosus”’, both names are used interchangeably herein, and both can be abbreviated as “L. rhamnosus”.
Doses
Preferably, vitamin C is administered in an amount such that its local concentration in the colon is at least 0.05 g/L, preferably at least 0.1 g/L, most preferably at least 0.33 g/L. Preferred local concentrations in the colon range from about 0.05 g/L to about 1.5 g/L, more preferably from about 0.1 g/L to about 1 g/L, most preferably from about 0.2 g/L to about 0.5 g/L. Specific dosages
per day can range up to 2000 mg/day, preferably 100-2000 mg/day; more preferably 200-1000 mg/day.
The dosage of the probiotic can be up to 5E+10 cfu/day. Preferably, the dosage range of the probiotic is from 1 E+08 to 1 E+10 cfu/day, more preferably from 1 E+09 to 5E+10 cfu/day.
Formulations
The vitamin (vitamin C ) and/or the probiotic (Lactobacillus rhamnosus), preferably both, is (are) preferably present in a formulation which allows the vitamin (and/or probiotic) to be available predominantly in the large intestine.
Oral formulations are preferred. Other formulations include non-oral routes, such as via suppositories or injections.
For human use, the preferred method is through a delayed-release form which delays delivery until the intestinal tract is reached. For non-human animals, a preferred delivery includes a method of administering a large enough dose so that only a portion of the vitamin and/or probiotic delivered is absorbed in the stomach, and the remainder, which is an effective dose, is available to the intestinal tract; although not preferred, this method of delivery can be used for humans as well.
Delayed-release formulations are known in the art. Preferably, the delayed-release formulations have an enteric coating (also referred to as enteric layer).
In one embodiment of the present invention, the vitamin and/or probiotic, preferably both, is in a formulation comprising an enteric capsule, filled with a composition comprising the vitamin and/or probiotic. The enteric capsule confers resistance against the acidic environment of the stomach. For example, soft gel formulations may deliver the active agent in solution and yet offer advantages of solid dosage forms.
In another embodiment, the formulation is a tablet comprising (i) a core comprising the vitamin and/or the probiotic, and (ii) a delayed-release coating such as an enteric coating. This may be a hard gel capsule.
Alternatively, for direct colon delivery, a matrix-based delivery system can be used. Matrix based systems have no discrete layer of coating material, but the active agent (i.e., the vitamin and/or the probiotic) is more or less homogenously distributed within the matrix. Further, there are colonrelease systems that embed the active agent in e.g. in a fiber matrix (enzyme-triggered) and an enteric coating on top.
The release of the vitamin and/or probiotic may be delayed until the small intestine. In another embodiment, the release is delayed until the distal small intestine. In yet another, preferred embodiment, the release of the vitamin and/or probiotic is delayed until the colon (large intestine).
In a preferred embodiment for humans, the vitamin and/or probiotic is formulated in a solid dosage form for oral administration. The formulation may be in the form of a capsule, pellet, bead, sphere, mini spheres, tablet, mini tablet, or granule, optionally coated with a delayed release coating that prevents the release of the active agent before the small intestine, preferably before the colon.
Coating, or matrix materials for the delayed release of the vitamin and/or probiotic, in particular for targeted release in the ileum or the large intestine upon oral administration are known in the art. They can be subdivided into coating materials that disintegrate above a specific pH, coating materials that disintegrate after a specific residence time in the gastrointestinal tract and coating materials that disintegrate due enzymatic triggers specific to the microflora of a specific region of the intestines. Coating materials from different categories are commonly used in combinations. Coating materials of the different categories for targeting to the large intestine have been reviewed for example in Bansal et al. (Polim. Med. 2014, 44, 2,109-118). In one embodiment of the present invention, the delayed-release coating comprises at least one component selected from coating materials that disintegrate pH-dependently, coating materials that disintegrate time-dependently, coating materials that disintegrate due to enzymatic triggers in the intestinal environment (e.g., in the intestinal environment of the ileum and the large intestine), and combinations thereof.
Coating materials that disintegrate pH-dependently include polyvinyl acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate HP-50, HP-55 or HP-55S, cellulose acetate phthalate, shellac, hydroxypropyl methylcellulose acetate succinate (HPMCAS), poly(methacrylic acid, ethyl acrylate) 1 :1 (Eudragit® L100-55, Eudragit® L30D-55), poly(methacrylic acid, methyl methacrylate) 1 :1 (Eudragit® L-100, Eudragit® L12.5), poly(methacrylic acid, methyl methacrylate) 1 :2 (Eudragit® S-100, Eudragit® S12,5, and
Eudragit® FS30D). Coating materials that disintegrate time-dependently include Eudragit® RL, Eudragit®RS, and ethylcellulose. Coating materials that disintegrate due to enzymatic triggers in the large intestinal environment include chondroitin sulfate, pectin, guar gum, chitosan, inulin, lactulose, raffinose, stachyose, alginate, dextran, xanthan gum, locust bean gum, arabinogalactan, cyclodextrin, pullulan, carrageenan, scleroglucan, chitin, curdulan, levan, amylopectin, starch, amylose, resistant starch, and azo compounds being degraded by azo bonds splitting bacteria.
The following non-limiting examples are presented to better illustrate the invention.
EXAMPLES
The aim of this study was to investigate the effect of a combination of vitamin C and Lactobacillus rhamnosus on the composition of the gut microbiota in a long-term continuous fermentation experiment.
Materials and Methods
Design of the long-term SHIME fermentation experiment (Colon Model)
The typical reactor setup of the SHIME®, representing the gastrointestinal tract of the adult human, was described by Molly et al. (1993) Applied Microbiology and Biotechnology 39(2):254- 258. Inoculum preparation, retention time, pH, temperature settings and reactor feed composition were previously described by Possemiers et al. (2004) FEMS Microbiol Ecol. 49(3):495-507. Compared to the typical setup of the SHIME, the long-term SHIME experiment used for this example included some adaptations. In one reactor, at first, the conditions of the stomach were simulated, before being changed by the computer to conditions simulating the small intestine. The suspension was then added to the colonic reactors mimicking the transverse colon (pH 6.15-6.4; retention time = 32h; volume of 800 mL).
The SHIME® experiment for this study consisted of three stages:
1. Stabilization period: After inoculation of the colon reactors with an appropriate fecal sample, a two-week stabilization period allowed the microbial community to differentiate in the different reactors depending on the local environmental conditions. During this period the basic nutritional matrix was provided to the SHIME to support the maximum diversity of the gut microbiota originally present in the faecal inoculum.
2. Control period: During this two-week reference period, the standard SHIME nutrient matrix was further dosed to the model for a period of 14 days. Analysis of samples in this period allowed to determine the baseline microbial community composition and activity in the different reactors, which is used as a reference for results obtained during the treatment.
3. Treatment: During this three-week period, the SHIME was operated under nominal conditions, but the appropriate probiotic strain and vitamin(s) were supplemented to the appropriate reactors. The probiotic strain was added to the reactors at a concentration of 1*1010 CFU/reactor. Vitamin C (Ascorbic acid, DSM) was added to the reactors at a dose of 200 mg/day.
The probiotic strain used in this experiment was the Lactobacillus rhamnosus GG equivalent Lactobacillus rhamnosus DSM 32550 (Biocare Copenhagen).
Lactobacillus rhamnosus DSM 32550 has a genomic sequence which is 99.99% identical to the genomic sequence of LGG®. It can therefore be considered that L. rhamnosus DSM 32550 is identical or equivalent to LGG® for practical purposes. In the Examples and Figures herein, Lactobacillus rhamnosus DSM 32550 will thus be referred to as a Lactobacillus rhamnosus GG strain.
Quantitative Microbial Community Analysis by 16S rRNA Gene Sequencing and Flow Cytometry
Samples for quantitative 16S-targeted Illumina sequencing were collected 3x/week during the last week of the control and treatment period. Next-generation 16S rRNA gene amplicon sequencing of the V3-V4 region was performed by LGC Genomics GmbH (Berlin, Germany) on samples from the medium-term SHIME experiment. Library preparation and sequencing were performed on an Illumina MiSeq platform with v3 chemistry. The 341 F (50-CCTACGGGNGGCWGCAG-30) and 785R (50- GACTACHVGGGTATCTAAKCC-30) primers were used as described by De Paepe et al. (2017) with the reverse primer being adapted to increase coverage. Quality control PCR was conducted using Taq DNA Polymerase with the Fermentas PCR Kit according to the manufacturers’ instructions (Thermo Fisher Scientific, Waltham, MA, USA). The DNA quality was verified by electrophoresis on a 2% (w/v) agarose gel for 30 min at 100 V. Bioinformatics analysis of amplicon data was performed as described by De Paepe et al. (2017). The obtained high- resolution proportional phylogenetic information (i.e., proportional abundances (%)) was combined with an accurate quantification of total bacterial cells via flow cytometry to obtain
quantitative data at phylum, family, and species level. This was done by multiplying the proportional abundances with absolute cell numbers (cells/mL) obtained via flow cytometry. For flow cytometry analysis, 10-fold serial dilutions were prepared in Dulbecco’s phosphate-buffered Saline (DPBS) (Sigma-Aldrich, Bomem, Belgium) of all samples and stained with 0.01 mM SYTO24 (Life Technologies Europe, Merelbeke, Belgium) for 15’ at 37°C in the dark. Samples were analyzed on a BD Facsverse (BDBiosciences, Erembodegem, Belgium) using the high-flow- rate setting and bacteria were separated from medium debris and signal noise by applying a threshold level of 200 on the SYTO channel.
Results
Supplementation of a combination of Lactobacillus rhamnosus GG and vitamin C increased the abundance of Firmicutes
As can be taken from Figure 1 , supplementation of Lactobacillus rhamnosus GG alone did not significantly change the abundance of Firmicutes compared to the control. In contrast, the combination of Lactobacillus rhamnosus GG and vitamin C significantly increased the abundance of Firmicutes compared to the control.
Supplementation of a combination of Lactobacillus rhamnosus GG and vitamin C increased the abundance of Lachnospiraceae
As can be taken from Figure 2, supplementation of Lactobacillus rhamnosus GG alone did not significantly change the abundance of Lachnospiraceae compared to the control. In contrast, the combination of Lactobacillus rhamnosus GG and vitamin C significantly increased the abundance of Lachnospiraceae compared to the control.
Supplementation of a combination of Lactobacillus rhamnosus GG and vitamin C increased the abundance of Blautia obeum/wexlerae
As can be taken from Figure 3, supplementation of Lactobacillus rhamnosus GG alone did not significantly change the abundance of Blautia obeum/wexlerae compared to the control. In contrast, the combination of Lactobacillus rhamnosus GG and vitamin C significantly increased the abundance of Blautia obeum/wexlerae compared to the control.
Claims
1 . Combination comprising vitamin C and Lactobacillus rhamnosus.
2. Combination according to claim 1 , wherein said combination comprises vitamin C and Lactobacillus rhamnosus GG.
3. Combination according to claim 1 or claim 2, wherein said combination is for simultaneous administration or consumption.
4. Combination according to claim 1 or claim 2, wherein said combination is for sequential administration or consumption.
5. Combination according to any one of claims 1-4, wherein said combination is an oral dosage form, and wherein said combination is more preferably a solid oral dosage form.
6. Combination according to any one of claims 1-5, wherein said combination is for administration to the large intestine.
7. Combination according to any one of claims 1-6 for use as a medicament, a dietary supplement, or a food supplement.
8. Combination according to any one of claims 1-7 for use in the treatment of a patient that is in need of increasing the abundance of Firmicutes and/or Lachnospiraceae in the large intestine.
9. Combination for the use according to claim 8, wherein said patient is in need of increasing the abundance of Lachnospiraceae and is suffering from ulcerative colitis or Crohn’s disease.
10. Combination according to any one of claims 1-7 for use in the treatment of a patient that is in need of increasing the abundance of Blautia, preferably Blautia obeum or Blautia wexlerae, in the large intestine.
Combination for the use according to claim 10, wherein said patient is suffering from one or more of the following: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity, insulin resistance, Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation. Combination comprising vitamin C and Lactobacillus rhamnosus for use in increasing the abundance of Firmicutes, Lachnospiraceae, and/or Blautia in the large intestine of an animal, preferably a human, wherein said use comprises administering or delivering the vitamin C and the Lactobacillus rhamnosus to the large intestine. Combination comprising vitamin C and Lactobacillus rhamnosus for the use according to claim 12, wherein the vitamin C and the Lactobacillus rhamnosus are administered or delivered to the large intestine by a delayed-release formulation. Combination comprising vitamin C and Lactobacillus rhamnosus for the use according to claim 12 or claim 13, wherein said use comprises administering or delivering the vitamin C and the Lactobacillus rhamnosus simultaneously and/or sequentially to the animal, preferably a human. Combination comprising vitamin C and Lactobacillus rhamnosus for the use according to any one of claims 12-14, wherein the animal, including a human, is experiencing a condition selected from: Alzheimer’s disease, ankylosing spondylitis, autism spectrum disorder, atopic dermatitis, cirrhosis, colorectal cancer, Crohn’s disease, Graves’ disease, HIV, IBD with Clostridium difficile infection, lung cancer; major depressive disorder (MDD), multiple system atrophy, neuromyelitis optica spectrum disorders (NMOSD), obesity, insulin resistance, Parkinson’s disease, preeclampsia, schizophrenia, severe acute pancreatitis, Sjogren's syndrome, Type 2 diabetes, ulcerative colitis, and visceral fat accumulation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22178531 | 2022-06-10 | ||
EP22178531.4 | 2022-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023237689A1 true WO2023237689A1 (en) | 2023-12-14 |
Family
ID=82115905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/065400 WO2023237689A1 (en) | 2022-06-10 | 2023-06-08 | Combinations comprising vitamin c and lactobacillus rhamnosus |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023237689A1 (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010130785A2 (en) * | 2009-05-12 | 2010-11-18 | Valio Ltd | Novel use of probiotics |
WO2015105437A1 (en) * | 2014-01-13 | 2015-07-16 | Ockerman Per-Arne | Multi nutrient supplementation |
EP3318262A2 (en) * | 2016-11-03 | 2018-05-09 | Cell Biotech Co., Ltd. | Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease |
CN108813262A (en) * | 2018-07-02 | 2018-11-16 | 杭州相生相成科技有限公司 | A kind of compound probiotic solid beverage containing DHA algal oil |
CN109125525A (en) * | 2017-06-16 | 2019-01-04 | 广州市康优元生物科技有限公司 | Composition of prevention and cure of cardiovascular disease and its preparation method and application |
WO2020043797A1 (en) | 2018-08-29 | 2020-03-05 | Dsm Ip Assets B.V. | Formulations for improving gut health |
CN111387387A (en) * | 2020-04-13 | 2020-07-10 | 山东国和堂制药有限公司 | Probiotic beverage for assisting in adjusting intestinal flora and preparation method thereof |
CN111802550A (en) * | 2020-07-28 | 2020-10-23 | 山东国和堂制药有限公司 | Probiotic formula beverage and preparation method thereof |
-
2023
- 2023-06-08 WO PCT/EP2023/065400 patent/WO2023237689A1/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010130785A2 (en) * | 2009-05-12 | 2010-11-18 | Valio Ltd | Novel use of probiotics |
WO2015105437A1 (en) * | 2014-01-13 | 2015-07-16 | Ockerman Per-Arne | Multi nutrient supplementation |
EP3318262A2 (en) * | 2016-11-03 | 2018-05-09 | Cell Biotech Co., Ltd. | Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease |
CN109125525A (en) * | 2017-06-16 | 2019-01-04 | 广州市康优元生物科技有限公司 | Composition of prevention and cure of cardiovascular disease and its preparation method and application |
CN108813262A (en) * | 2018-07-02 | 2018-11-16 | 杭州相生相成科技有限公司 | A kind of compound probiotic solid beverage containing DHA algal oil |
WO2020043797A1 (en) | 2018-08-29 | 2020-03-05 | Dsm Ip Assets B.V. | Formulations for improving gut health |
CN111387387A (en) * | 2020-04-13 | 2020-07-10 | 山东国和堂制药有限公司 | Probiotic beverage for assisting in adjusting intestinal flora and preparation method thereof |
CN111802550A (en) * | 2020-07-28 | 2020-10-23 | 山东国和堂制药有限公司 | Probiotic formula beverage and preparation method thereof |
Non-Patent Citations (13)
Title |
---|
ALAVI S., INTERPERSONAL GUT MICROBIOME VARIATION DRIVES SUSCEPTIBILITY AND RESISTANCE TO CHOLERA INFECTION, 2020 |
BANSAL ET AL., POLIM. MED., vol. 44, no. 2, 2014, pages 109 - 118 |
HAMER HM ET AL., THE ROLE OF BUTYRATE ON COLONIC FUNCTION, 2008 |
HATZIIOANOU D ET AL., DISCOVERY OF A NOVEL LANTIBIOTIC NISIN O FROM BLAUTIA OBEUM A2-162, ISOLATED FROM THE HUMAN GASTROINTESTINAL TRACT, 2017 |
KOH, A ET AL., FROM DIETARY FIBER TO HOST PHYSIOLOGY: SHORT- CHAIN FATTY ACIDS AS KEY BACTERIAL METABOLITES, 2016 |
LOZUPONE, CA ET AL., DIVERSITY, STABILITY AND RESILIENCE OF THE HUMAN GUT MICROBIOTA, 2012 |
MOLLY ET AL., APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 39, no. 2, 1993, pages 254 - 258 |
POSSEMIERS ET AL., FEMS MICROBIOL ECOL, vol. 49, no. 3, 2004, pages 495 - 507 |
RINNINELLA ET AL.: "What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age", ENVIRONMENT, DIET, AND DISEASES, 2019 |
SASAKI, K ET AL., CONSTRUCTION OF A MODEL CULTURE SYSTEM OF HUMAN COLONIC MICROBIOTA TO DETECT DECREASED LACHNOSPIRACEAE ABUNDANCE AND BUTYROGENESIS IN THE FECES OF ULCERATIVE COLITIS PATIENTS, 2019 |
VACCA MIRCO ET AL: "The Controversial Role of Human Gut Lachnospiraceae", MICROORGANISMS, vol. 8, no. 4, 15 April 2020 (2020-04-15), XP055882124, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232163/pdf/microorganisms-08-00573.pdf> DOI: 10.3390/microorganisms8040573 * |
VACCA, M ET AL., THE CONTROVERSIAL ROLE OF HUMAN GUT LACHNOSPIRACEAE, 2020 |
YONG SHIN JIE ET AL: "Antidepressive Mechanisms of Probiotics and Their Therapeutic Potential", FRONTIERS IN NEUROSCIENCE, vol. 13, 14 January 2020 (2020-01-14), XP093077807, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971226/pdf/fnins-13-01361.pdf> DOI: 10.3389/fnins.2019.01361 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7407120B2 (en) | synbiotic composition | |
US8481025B2 (en) | Composition for maintaining healthy kidney function | |
AU2010305515B2 (en) | Lactobacillus plantarum strains as hypocholesterolemic agents. | |
WO2023237689A1 (en) | Combinations comprising vitamin c and lactobacillus rhamnosus | |
US20230404970A1 (en) | Direct delivery of vitamins to rebalance gut microbiome after exposure to antibiotics | |
JP2005532294A (en) | Compositions and methods for enhancing renal function | |
WO2023237673A1 (en) | Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis | |
WO2023237684A1 (en) | Combinations comprising vitamin c and lactobacillus rhamnosus | |
WO2023237687A1 (en) | Combinations comprising vitamin b2 and lactobacillus rhamnosus | |
WO2023237678A1 (en) | Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis | |
WO2023237677A1 (en) | Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis | |
WO2023237680A1 (en) | Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis | |
WO2018125735A1 (en) | Composition and method for maintaining healthy kidney function | |
WO2023237682A1 (en) | Combinations comprising vitamin b2 and lactobacillus rhamnosus | |
WO2023237683A1 (en) | Combinations comprising vitamin c and bacillus coagulans | |
WO2023237685A1 (en) | Combinations comprising vitamin and bacillus coagulans | |
WO2023237688A1 (en) | Combinations comprising vitamin c and lactobacillus rhamnosus | |
WO2023237679A1 (en) | Combinations comprising vitamin b2 and lactobacillus rhamnosus | |
WO2023237676A1 (en) | Vitamins for use in improving gut health | |
WO2023237686A1 (en) | Combinations comprising vitamin c and lactobacillus rhamnosus | |
WO2023237681A1 (en) | Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis | |
US20230270705A1 (en) | Method of increasing the population of dialister spp. in the gut microbiome | |
RU2799354C2 (en) | Synbiotic compositions | |
WO2023237674A1 (en) | Vitamin b2 for use in improving gut health | |
WO2023237675A1 (en) | Vitamin b2 for use in improving gut health |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23733227 Country of ref document: EP Kind code of ref document: A1 |